Research ExplorerJournalsMOL CANCER THER Publications

MOL CANCER THER - Molecular cancer therapeutics

1 - 16 out of 16Page size: 50

Publications

  1. 2019

  2. An EGFR-induced Drosophila lung tumor model identifies alternative combination treatments

    Bossen, J., Uliczka, K., Steen, L., Pfefferkorn, R., Mai, M. M-Q., Burkhardt, L., Spohn, M., Bruchhaus, I., Fink, C., Heine, H. & Roeder, T., 09.2019, In: MOL CANCER THER. 18, 9, p. 1659-1668 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies

    Tintelnot, J., Baum, N., Schultheiss, C., Braig, F., Trentmann, M., Finter, J., Fumey, W., Bannas, P., Fehse, B., Riecken, K., Schütze, K., Bokemeyer, C., Rösner, T., Valerius, T., Peipp, M., Koch-Nolte, F. & Binder, M., 04.2019, In: MOL CANCER THER. 18, 4, p. 823-833 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. 2017

  5. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

    Press, M. F., Ellis, C. E., Gagnon, R. C., Grob, T. J., Buyse, M., Villalobos, I., Liang, Z., Wu, S., Bang, Y-J., Qin, S-K., Chung, H. C., Xu, J., Park, J. O., Jeziorski, K., Afenjar, K., Ma, Y., Estrada, M. C., Robinson, D. M., Scherer, S. J., Sauter, G., Hecht, J. R. & Slamon, D. J., 01.2017, In: MOL CANCER THER. 16, 1, p. 228-238 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. 2016

  7. Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs

    Berte, N., Piée-Staffa, A., Piecha, N., Wang, M., Borgmann, K., Kaina, B. & Nikolova, T., 11.2016, In: MOL CANCER THER. 15, 11, p. 2665-2678 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma

    Yu, Y., Schönlein, M., Kaufmann, A. M., Dörken, B. & Schmitt, C. A., 05.2016, In: MOL CANCER THER. 15, 5, p. 1074-81 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. 2014

  10. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma

    Ilieva, K. M., Correa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M. J., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E. & Karagiannis, S. N., 12.2014, In: MOL CANCER THER. 13, 12, p. 2769-83 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)

    Decker, S., Finter, J., Forde, A. J., Kissel, S., Schwaller, J., Mack, T. S., Kuhn, A., Gray, N., Follo, M., Jumaa, H., Burger, M., Zirlik, K., Pfeifer, D., Miduturu, C. V., Eibel, H., Veelken, H. & Dierks, C., 05.2014, In: MOL CANCER THER. 13, 5, p. 1231-45 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells

    Happold, C., Roth, P., Silginer, M., Florea, A-M., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G. & Weller, M., 2014, In: MOL CANCER THER. 13, 4, p. 948-961 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. 2013

  14. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer

    Henningsen, M., zu Eulenburg, C., Kolarova, T., Qi, J. W., Manivong, K., Chalukya, M., Dering, J., Anderson, L., Ginther, C., Meuter, A., Winterhoff, B., Jones, S., Velculescu, V. E., Venkatesan, N., Rong, H-M., Dandekar, S., Udar, N., Jänicke, F., Los, G., Slamon, D. J. & Konecny, G. E., 01.06.2013, In: MOL CANCER THER. 12, 6, p. 1002-15 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. 2010

  16. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib

    Giovannetti, E., Zucali, P. A., Peters, G. J., Cortesi, F., D'Incecco, A., Smit, E. F., Falcone, A., Burgers, J. A., Santoro, A., Danesi, R., Giaccone, G. & Tibaldi, C., 03.2010, In: MOL CANCER THER. 9, 3, p. 581-93 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD.

    Shalaby, T., von Bueren, A., André, O., Hürlimann, M-L., Fiaschetti, G., Castelletti, D., Masayuki, T., Nagasawa, K., Arcaro, A., Jelesarov, I., Shin-ya, K. & Grotzer, M., 2010, In: MOL CANCER THER. 9, 1, p. 167-179 1.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma.

    Gros, S., Kurschat, N., Dohrmann, T., Reichelt, U., Dancau, A. M., Peldschus, K., Adam, G., Hoffman, R. M., Izbicki, J. R. & Kaifi, J., 2010, In: MOL CANCER THER. 9, 7, p. 2037-2045 7.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  19. 2009

  20. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines

    Crea, F., Giovannetti, E., Cortesi, F., Mey, V., Nannizzi, S., Gallegos Ruiz, M. I., Ricciardi, S., Del Tacca, M., Peters, G. J. & Danesi, R., 07.2009, In: MOL CANCER THER. 8, 7, p. 1964-73 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.

    Trepel, M., Stoneham, C. A., Eleftherohorinou, H., Mazarakis, N. D., Pasqualini, R., Arap, W. & Hajitou, A., 2009, In: MOL CANCER THER. 8, 8, p. 2383-2391 8.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.

    Schittenhelm, M. M., Kollmannsberger, C., Oechsle, K., Harlow, A., Morich, J., Honecker, F., Kurek, R., Störkel, S., Kanz, L., Corless, C. L., Wong, K-K., Bokemeyer, C. & Heinrich, M. C., 2009, In: MOL CANCER THER. 8, 3, p. 481-489 3.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. 2008

  24. Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

    Distler, U., Souady, J., Hülsewig, M., Drmić-Hofman, I., Haier, J., Denz, A., Grützmann, R., Pilarsky, C., Senninger, N., Dreisewerd, K., Berkenkamp, S., Schmidt, M. A., Peter-Katalinic, J. & Müthing, J., 08.2008, In: MOL CANCER THER. 7, 8, p. 2464-75 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review